[1] |
Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.
Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study
[J]. Journal of International Oncology, 2024, 51(6): 326-331.
|
[2] |
Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.
Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer
[J]. Journal of International Oncology, 2024, 51(6): 332-337.
|
[3] |
Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.
Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy
[J]. Journal of International Oncology, 2024, 51(5): 257-266.
|
[4] |
Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.
Study on the clinical relationship between inflammatory burden index and gastric cancer
[J]. Journal of International Oncology, 2024, 51(5): 274-279.
|
[5] |
Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.
Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction
[J]. Journal of International Oncology, 2024, 51(4): 193-197.
|
[6] |
Wang Kun, Zhou Zhongxin, Zang Qiwei.
Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection
[J]. Journal of International Oncology, 2024, 51(4): 198-203.
|
[7] |
Wan Fang, Yang Gang, Li Rui, Wan Qijing.
Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer
[J]. Journal of International Oncology, 2024, 51(4): 204-209.
|
[8] |
Yao Yixin, Shen Yulin.
Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE
[J]. Journal of International Oncology, 2024, 51(4): 217-222.
|
[9] |
Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin.
Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(3): 137-142.
|
[10] |
Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.
Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes
[J]. Journal of International Oncology, 2024, 51(3): 143-150.
|
[11] |
Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.
Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer
[J]. Journal of International Oncology, 2024, 51(3): 175-180.
|
[12] |
Peng Qin, Cai Yuting, Wang Wei.
Advances on KPNA2 in liver cancer
[J]. Journal of International Oncology, 2024, 51(3): 181-185.
|
[13] |
Chen Boguang, Wang Sugui, Zhang Yongjie.
Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer
[J]. Journal of International Oncology, 2024, 51(2): 73-82.
|
[14] |
Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.
Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(2): 89-94.
|
[15] |
Jin Xudong, Chen Zhongjian, Mao Weimin.
Research progress on the role of MTAP in malignant mesothelioma
[J]. Journal of International Oncology, 2024, 51(2): 99-104.
|